Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02448810 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02448810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02448810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Lead sponsor
Baxalta now part of Shire
Phase
Phase 2
Overall status
Terminated
Start date
June 15, 2015
Completion date
February 15, 2017
Enrollment
115 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer